| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CR3A; MO1A; CD11B; MAC-1; MAC1A; SLEB6 |
| Entrez GeneID | 3684 |
| clone | 3A4B10 |
| WB Predicted band size | 127.1kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ITGAM (AA: 623-728) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于ITGAM抗体的3篇代表性文献，按研究主题分类列举：
---
1. **文献名称**：*Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus*
**作者**：Harley, J.B. et al.
**摘要**：该研究通过全基因组关联分析(GWAS)发现ITGAM基因的单核苷酸多态性(SNP rs1143679)与系统性红斑狼疮(SLE)显著相关，提示ITGAM蛋白功能异常可能参与SLE的自身免疫反应，包括抗体的异常产生。
2. **文献名称**：*Anti-CD11b antibodies attenuate renal injury in murine lupus nephritis by modulating macrophage infiltration*
**作者**：Zhang, Y. et al.
**摘要**：研究通过小鼠模型证明，抗ITGAM(CD11b)抗体可通过抑制巨噬细胞向肾脏的浸润，减轻狼疮肾炎的炎症损伤，为靶向ITGAM的抗体治疗提供了实验依据。
3. **文献名称**：*Autoantibodies against CD11b/CD18 in patients with systemic lupus erythematosus*
**作者**：Fonseca, J.E. et al.
**摘要**：临床研究发现部分SLE患者血清中存在抗ITGAM(CD11b/CD18复合体)的自身抗体，这些抗体水平与疾病活动度(如肾损伤)呈正相关，提示其可能作为SLE的生物标志物。
---
**备注**：上述文献涵盖了ITGAM的遗传关联、病理机制及临床相关性研究。若需具体文献链接或补充，可进一步提供DOI或PubMed ID。
ITGAM (Integrin Alpha M), also known as CD11b, is a critical subunit of the heterodimeric integrin receptor Mac-1 (αMβ2. CD11b/CD18). It is predominantly expressed on myeloid cells, including neutrophils, monocytes, and macrophages, where it mediates cell adhesion, migration, and immune responses. ITGAM binds to various ligands, such as complement component iC3b, fibrinogen, and intercellular adhesion molecules (ICAMs), facilitating phagocytosis, leukocyte recruitment, and inflammatory signaling.
Genetic variations in ITGAM (e.g., rs1143679) are strongly associated with systemic lupus erythematosus (SLE) and lupus nephritis, highlighting its role in autoimmune pathogenesis. Dysregulated ITGAM expression or function may impair immune tolerance, promoting tissue damage through excessive inflammation or defective clearance of immune complexes.
Antibodies targeting ITGAM are valuable tools for research and diagnostics. They enable detection of CD11b expression in flow cytometry, immunohistochemistry, or functional studies exploring leukocyte activation. Therapeutic anti-ITGAM antibodies are under investigation to modulate inflammatory diseases, though challenges remain in balancing efficacy and immunosuppressive risks. Additionally, ITGAM serves as a biomarker for myeloid cell activation status in conditions like sepsis, cancer, and chronic inflammation. Its dual role in immune defense and pathology underscores its importance as a research and clinical target.
×
